

## Editor

Tore K Kvien

## Associate Editors

Francis Berenbaum  
Hans Bijlsma  
David Pisetsky  
Dimitrios Boumpas  
Gerd Burmester  
Mary Crow  
Iain McInnes

## Editorial office

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 7383 6250  
F: +44 (0)20 7383 6668  
E: [ard@bmj.com](mailto:ard@bmj.com)  
Twitter: @ARD\_BMJ  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)  
Impact Factor: 9.270

**Disclaimer:** ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

**Copyright:** © 2014 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Teichset and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431  
POSTMASTER: send address changes to Annals of the Rheumatic Diseases, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.



Receive regular table of contents by email.  
Register using this QR code.

## Editorial

- 2065** Rheumatological diseases and cancer: the hidden variable of radiation exposure  
*E Picano, R Semelka, J Ravenel, M Matucci-Cerinic*

## Clinical and epidemiological research

- 2069** Screening for interstitial lung disease in systemic sclerosis: performance of high-resolution CT with limited number of slices: a prospective study  
*T Frauenfelder, A Winklehner, T D L Nguyen, R Dobrota, S Baumweller, B Maurer, O Distler*
- 2074** Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial  
*R Seror, G Baron, E Hachulla, M Debandt, C Larroche, X Puéchal, F Maurier, B de Wazieres, T Quémeiner, P Ravauud, X Mariette*
- 2082** The effect of *FTO* variation on increased osteoarthritis risk is mediated through body mass index: a mendelian randomisation study  
*K Panoutsopoulou, S Metrustry, S A Doherty, L L Laslett, R A Maciewicz, D J Hart, W Zhang, K R Muir, M Wheeler, C Cooper, T D Spector, F M Cicuttini, G Jones, N K Arden, M Doherty, E Zeggini, A M Valdes, arcOGEN Consortium*
- 2087** Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis  
*T Minier, S Guiducci, S Bellando-Randone, C Bruni, G Lepri, L Czirják, O Distler, U A Walker, J Fransen, Y Allanoire, C Denton, M Cutolo, A Tyndall, U Müller-Ladner, M Matucci-Cerinic, and the EUSTAR co-workers*
- 2094** Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension  
*E Keystone, R Landewé, R van Vollenhoven, B Combe, V Strand, P Mease, L Shaughnessy, B VanLunen, D van der Heijde*
- 2101** Sugar-sweetened beverage consumption: a risk factor for prevalent gout with *SLC2A9* genotype-specific effects on serum urate and risk of gout  
*C Batt, A J Phipps-Green, M A Black, M Cadzow, M E Merriman, R Topless, P Gow, A Harrison, J Highton, P Jones, L Stamp, N Dalbeth, T R Merriman*
- 2107** Racial disparities in knee and hip total joint arthroplasty: an 18-year analysis of national medicare data  
*J A Singh, X Lu, G E Rosenthal, S Ibrahim, P Crum*
- 2116** Prediction model for knee osteoarthritis incidence, including clinical, genetic and biochemical risk factors  
*H J M Kerkhof, S M A Bierma-Zeinstra, N K Arden, S Metrustry, M Castano-Betancourt, D J Hart, A Hofman, F Rivadeneira, E H G Oei, T D Spector, A G Uitterlinden, A C J W Janssens, A M Valdes, J B J van Meurs*
- 2122** Validation of the educational needs assessment tool as a generic instrument for rheumatic diseases in seven European countries  
*M Ndoi, A Bremander, B Harnnes, M Horton, M L Kukkurainen, P Machado, A Marques, J Meesters, T A Stamm, A Tennant, J de la Torre-Aboki, T P M Vliet Vlieland, H A Zangi, J Hill*

- 2130** A meta-analysis of genome-wide association studies identifies novel variants associated with osteoarthritis of the hip  
*E Evangelou, H J Kerkhof, U Styrkarsdottir, E E Ntzani, S D Bos, T Esko, D S Evans, S Metrustry, K Panoutsopoulou, Y F M Ramos, G Thorleifsson, K K Tsilidis, arcOGEN Consortium, N Arden, N Aslam, N Bellamy, F Birrell, F J Blanco, A Carr, K Chapman, A G Day-Williams, P Deloukas, M Doherty, G Engström, H T Helgadottir, A Hofman, T Ingvarsson, H Jonsson, A Keis, J C Keurentjes, M Kloppenburg, PA Lind, A McCaskie, N G Marin, L Milani, G W Montgomery, R G H H Nelissen, M C Nevitt, P M Nilsson, W ER Ollier, N Parimi, A Rai, S H Ralston, M R Reed, J A Riancho, F Rivadeneira, C Rodriguez-Fontenla, L Southam, U Thorsteinsdottir, A Tsezou, G A Wallis, J M Wilkinson, A Gonzalez, N E Lane, L S Lohmander, J Loughlin, A Metspalu, A G Uitterlinden, I Jonsdottir, K Stefansson, P E Slagboom, E Zeggini, I Meulenbelt, J PA Ioannidis, T D Spector, J B J van Meurs, A M Valdes*

- 2137** Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis  
*D Poddubnyy, K Conrad, H Haibel, U Syrbe, H Appel, J Braun, M Rudwaleit, J Sieper*

- 2144** The Canadian Methotrexate and Etanercept Outcome Study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis  
*J E Pope, B Haraoui, J C Thorne, A Vieira, M Poulin-Costello, E C Keystone*

- 2152** Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial  
*M E Weinblatt, R Westhovens, A M Mendelsohn, L Kim, K H Lo, S Sheng, L Noonan, J Lu, Z Xu, J Leu, D Baker, C O Bingham, on behalf of the GO-FURTHER investigators*

- 2160** The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry  
*H J Lachmann, R Papa, K Gerhold, L Obici, I Touitou, L Cantarini, J Frenkel, J Anton, I Kone-Paut, M Catalini, B Bader-Meunier, A Insalaco, V Hentgen, R Merino, C Modesto, N Toplak, R Berendes, S Ozen, R Cimaz, A Jansson, P A Brogan, P N Hawkins, N Ruperto, A Martini, P Woo, M Gattorno, for the Paediatric Rheumatology International Trials Organisation (PRINTO), the EUROTRAPS and the Eurofever Project*

## MORE CONTENTS ►



This article has been chosen by the Editor to be of special interest or importance and is freely available online.




This article has been made freely available online under the BMJ Journals Open Access scheme. See <http://ard.bmj.com/site/about/guidelines.xhtml#open>



This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



- 2168** Validation of the Auto-Inflammatory Diseases Activity Index (AIDAI) for hereditary recurrent fever syndromes  
 *M Piram, I Koné-Paut, H J Lachmann, J Frenkel, S Ozen, J Kuemmerle-Deschner, S Stojanov, A Simon, M Finetti, M P Sormani, A Martini, M Gattorno, N Ruperto, on the behalf of EUROFEVER, EUROTRAPS and the Paediatric Rheumatology International Trials Organisation (PRINTO) networks*

- 2174** Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase  
*M H Schiff, J von Kempis, R Goldblum, J R Tesser, R B Mueller*

- 2178** Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up  
*E H Vogelzang, E L Kneepkens, M T Nurmohamed, A W R van Kuijk, T Rispen, G Wolbink, C L M Krieckaert*

### Basic and translational research

- 2183** Amelioration of experimental arthritis by stroke-induced immunosuppression is independent of T<sub>reg</sub> cell function  
 *I M Irmiler, M Gajda, T Kamradt*

- 2192** The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells  
*S Kubo, K Yamaoka, M Kondo, K Yamagata, J Zhao, S Iwata, Y Tanaka*

- 2199** TLR9 independent interferon  $\alpha$  production by neutrophils on NETosis in response to circulating chromatin, a key lupus autoantigen  
*D Lindau, J Mussard, A Rabsteyn, M Ribon, I Köter, A Igney, G J Adema, M-C Boissier, H-G Rammensee, P Decker*

- 2208** Knee and hip articular cartilage have distinct epigenomic landscapes: implications for future cartilage regeneration approaches  
*W den Hollander, Y F M Ramos, S D Bos, N Bomer, R van der Breggen, N Lakenberg, W J de Dijkster, B J Duijnisveld, P E Slagboom, R G H H Nelissen, I Meulenbelt*

### Letters

- 2213** Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro  
*S-P Wang, S Iwata, S Nakayamada, K Sakata, K Yamaoka, Y Tanaka*

- 2215** Anakinra for the management of resistant idiopathic recurrent pericarditis. Initial experience in 10 adult cases  
*G Lazaros, P Vasileiou, C Koutsianas, K Antonatou, C Stefanadis, D Pectasides, D Vassilopoulos*

- 2217** Golimumab trough levels, antidrug antibodies and clinical response in patients with rheumatoid arthritis treated in daily clinical practice  
*E L Kneepkens, C Plasencia, C L M Krieckaert, D Pascual-Salcedo, D van der Kleij, M T Nurmohamed, M T López-Casla, R Wieringa, T Rispen, G Wolbink*

- 2219** Combination of MRI-detected bone marrow oedema with 2010 rheumatoid arthritis classification criteria improves the diagnostic probability of early rheumatoid arthritis  
*M Tamai, J Kita, Y Nakashima, T Suzuki, Y Horai, A Okada, T Koga, Shin-ya Kawashiri, N Iwamoto, K Ichinose, K Arima, S Yamasaki, H Nakamura, T Origuchi, M Uetani, A Fukushima, K Aoyagi, K Eguchi, A Kawakami*

### Electronic pages

- e75** Bivalent HPV vaccine safety depending on subtypes of juvenile idiopathic arthritis  
*S Akioka*

- e76** Response to: 'Bivalent HPV vaccine safety depending on subtypes of juvenile idiopathic arthritis' by Dr Akioka  
*M W Heijstek, N M Wulffraat*

- e77** Comment on 'Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry'  
*E Feldtkeller, M Rudwaleit*

- e78** Reply to eLetter by Feldtkeller *et al*  
*J Sørensen, M L Heiland*

- e79** Response to: 'Obesity and comorbidity are independently associated with a failure to achieve remission in patients with established rheumatoid arthritis' by Ellerby *et al*  
*M E C Sandberg, C Bengtsson, H Källberg, A Wesley, L Klareskog, L Alfredsson, S Saevarsdottir*